India · Delayed Price · Currency is INR OneSource Specialty Pharma Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY 2027 saw 37% revenue and 39% EBITDA growth year-over-year, driven by semaglutide launches, new contracts, and capacity expansions. The company reaffirmed FY 2028 guidance and expects continued growth from biologics, drug device, and soft gelatin segments.
Fiscal Year 2026
-
Q4 FY 2026 saw a strong sequential recovery with 47% revenue growth, driven by semaglutide launches and capacity expansion. The company reaffirmed its FY 2028 guidance of $400 million revenue and 40% EBITDA margin, with robust demand and new approvals supporting future growth.
-
Q3 FY 2026 saw a 26% revenue decline due to delayed semaglutide approvals in Canada, impacting EBITDA and PAT. Despite near-term softness, robust demand, capacity expansion, and strong customer relationships support confidence in achieving FY 2028 guidance of $400 million revenue and $160 million EBITDA.
-
Q2 and H1 FY2026 saw strong revenue and EBITDA growth, driven by robust demand and successful capacity expansion. The company reiterated its FY2028 revenue outlook of $500 million, with major launches and capacity additions planned, while maintaining a diversified customer base and strong compliance record.
-
Q1 FY 2026 saw 12% revenue growth and a 37% rise in EBITDA, with margins up 500 bps year-over-year. Strong order book and take-or-pay contracts support accelerated CapEx and robust outlook, while potential acquisitions could significantly boost future revenue and EBITDA.
Fiscal Year 2025
-
Q4 and FY 2025 saw robust revenue and EBITDA growth, driven by new customer wins and strong DDC execution. The company maintains its FY 2028 guidance, with FY 2026 expected to be transitional due to regulatory timing, and continues to invest in capacity and integration.
-
Strong Q3 performance with 18% revenue growth and 36% EBITDA margin, driven by expanding GLP-1 and biologics segments. Medium-term guidance targets 25%-30% CAGR and $400M revenue, with significant CapEx planned for capacity expansion and a goal to be debt-free by FY27.